Nanobody Patents

Nanobody / single-domain antibody (VHH) patents cover VHH-scaffold innovations; humanization innovations; multivalent/multispecific-format innovations; and discovery-platform and delivery/half-life innovations — with IP held by Ablynx/Sanofi (the pioneer), camelid/VHH and shark-VNAR players, and academia (in a field of the smallest functional antibody fragments). WHY NANOBODIES / SINGLE-DOMAIN ANTIBODIES: NANOBODIES (single-domain antibodies, sdAbs, or VHHs) are the smallest functional ANTIBODY fragments — derived from the unusual heavy-chain-only antibodies naturally made by CAMELIDS (llamas/alpacas) and sharks (VNAR) — that bind targets with antibody-like specificity but are about 10× SMALLER than a conventional antibody; this tiny size gives advantages full antibodies LACK: deeper TISSUE/tumor PENETRATION, the ability to reach HIDDEN/cryptic epitopes (enzyme active sites, receptor clefts, viral pockets) that bulky antibodies can't, high thermal/chemical STABILITY, cheap MICROBIAL production, and easy modular assembly into MULTIVALENT/multispecific formats; a versatile antibody-alternative modality (the first approved nanobody drug is Sanofi/Ablynx's Cablivi/caplacizumab). MAJOR HOLDERS: ABLYNX (Sanofi — the Nanobody pioneer, foundational VHH IP), plus camelid/VHH and shark-VNAR companies and academic IP. VHH scaffolds, humanization, multivalent/multispecific formats, discovery platforms, and delivery/half-life are the core nanobody patent domains — and scaffolds, humanization, multivalent formats, and delivery are the open whitespace.

VHH-scaffold innovations; humanization innovations; multivalent/multispecific-format innovations; and specific-nanobody-composition innovations represent core nanobody patent domains — and the single-domain format, making it human-compatible, and assembling multi-target constructs are the foundational, high-value capabilities. VHH-SCAFFOLD PATENTS: the single-domain VHH STRUCTURE (the variable domain of a heavy-chain-only antibody) and its engineering — stability, solubility, the framework, and the long CDR3 loop that reaches cryptic epitopes; the VHH scaffold/format and engineering are core IP (Ablynx held foundational format IP — much now expiring/expired, opening the field, but specific engineered scaffolds remain patentable). HUMANIZATION PATENTS: camelid-derived VHHs must be HUMANIZED (mutating the framework toward human sequence) to reduce IMMUNOGENICITY for repeated therapeutic use, while keeping affinity/stability; humanization methods are high-value IP (humanization is a key, sometimes contentious therapeutic step). MULTIVALENT / MULTISPECIFIC-FORMAT PATENTS: a major nanobody ADVANTAGE — because they're small, single-domain, and stable, nanobodies are easily and modularly LINKED into MULTIVALENT (multiple copies for avidity) and MULTISPECIFIC (binding several targets) constructs (bi/tri-specifics, T-cell engagers, etc. — Cablivi is bivalent); multivalent/multispecific-format methods are high-value, distinctive IP (modular multi-target assembly is a key reason to use nanobodies — overlaps bispecific antibodies). SPECIFIC-NANOBODY-COMPOSITION PATENTS: the specific nanobody (sequence) binding a given target — composition-of-matter IP per nanobody-target pair (the nanobody is the drug). VHH scaffolds, humanization, multivalent/multispecific formats, and specific compositions are the highest-value core IP because the small format, human compatibility, and modular multi-target assembly are exactly what define nanobody therapeutics.

Discovery-platform innovations; delivery/half-life innovations; tissue-penetration/cryptic-epitope innovations; and application/§112 innovations represent additional nanobody patent domains — and finding nanobodies, managing their fast clearance (while exploiting their small size), and applications are where therapeutic value and challenges concentrate. DISCOVERY-PLATFORM PATENTS: the discovery ENGINE — IMMUNIZING camelids (llamas/alpacas) and building VHH LIBRARIES, then DISPLAY/selection (phage/yeast) of high-affinity, specific nanobodies; discovery-platform methods are high-value IP (the platform that finds good nanobodies is a durable engine). DELIVERY / HALF-LIFE PATENTS: a double-edged trait — nanobodies are CLEARED rapidly (their small size means fast kidney clearance), so for systemic therapy HALF-LIFE EXTENSION (fusing an anti-ALBUMIN nanobody, PEGylation, or Fc fusion) is often needed; BUT their small size also enables NOVEL delivery — INHALED (pulmonary), intracellular ('intrabodies'), oral/gut, and potentially crossing the BLOOD-BRAIN BARRIER; half-life-extension and novel-delivery methods are high-value, distinctive IP (managing clearance, or exploiting small size for new routes, is central). TISSUE-PENETRATION / CRYPTIC-EPITOPE PATENTS: exploiting the small size to PENETRATE dense tumors/tissue and bind CRYPTIC epitopes (enzyme active sites, GPCR/ion-channel pockets, viral conserved sites) that antibodies can't reach; tissue-penetration/cryptic-epitope methods are high-value (a defining advantage over antibodies). APPLICATION / §112 PATENTS: therapeutics, IMAGING (small + fast clearance is great for diagnostic imaging tracers), and diagnostics; and §112 enablement for nanobody genus claims; application methods are valuable. Discovery platforms, delivery/half-life, tissue penetration/cryptic epitopes, and applications are the highest-value application IP because finding nanobodies, managing/exploiting their size, reaching unreachable targets, and the right applications are exactly what make nanobodies valuable.

Nanobody startup IP strategy must navigate Ablynx/Sanofi's foundational VHH portfolio (the pioneering format IP — much now EXPIRING/expired, which has OPENED the nanobody field to new entrants, a key timing reality), conventional-antibody and bispecific IP overlap (multivalent/multispecific nanobody constructs overlap bispecific-antibody IP), the camelid-VHH-vs-shark-VNAR and synthetic-library options, the humanization requirement (and any humanization-method IP), the half-life challenge (fast clearance — half-life extension is often needed), the tissue-penetration/cryptic-epitope advantage (the key differentiator vs antibodies), the §112 enablement bar, the heavy clinical/FDA path, and a landscape where engineered scaffolds, humanization, multivalent formats, discovery, delivery, and specific compositions are the durable assets; understand that foundational format IP is largely expiring (opening the field), so the durable IP is in specific nanobody/target compositions, engineered scaffolds, humanization, multivalent/multispecific formats, half-life/novel delivery, and discovery platforms — with specific nanobodies, formats, and discovery often the real moat, and that affinity/specificity, the small-size advantages (penetration/cryptic epitopes/novel delivery), clinical efficacy, and FTO matter as much as patents; identify whitespace in formats, delivery, and cryptic-epitope targets. NANOBODY STARTUP IP STRATEGY: SPECIFIC NANOBODY/TARGET COMPOSITIONS, ENGINEERED SCAFFOLDS, HUMANIZATION, MULTIVALENT/MULTISPECIFIC FORMATS, HALF-LIFE/NOVEL DELIVERY, AND DISCOVERY PLATFORMS ARE THE IP: patent specific nanobody/target compositions, engineered scaffolds, humanization, multivalent/multispecific formats, half-life/novel delivery, and discovery platforms; FOUNDATIONAL FORMAT IP IS LARGELY EXPIRING — THE FIELD IS OPENING (KEY TIMING): Ablynx's pioneering VHH format patents are mostly expired/expiring, removing a major barrier and OPENING nanobodies to new entrants — a favorable timing reality (but check remaining/engineered-scaffold IP); SPECIFIC NANOBODY/TARGET COMPOSITIONS ARE THE CORE ASSET: the specific nanobody binding a target is composition-of-matter IP (the drug); MULTIVALENT/MULTISPECIFIC FORMATS ARE A KEY ADVANTAGE (BUT OVERLAP BISPECIFIC IP): easy modular multi-target/multivalent assembly is a major reason to use nanobodies — high-value, but overlaps bispecific-antibody IP (FTO); TISSUE PENETRATION + CRYPTIC EPITOPES ARE THE DEFINING DIFFERENTIATOR: small size reaches tumors/tissue and binds hidden epitopes (enzyme active sites/GPCR pockets) antibodies can't — target these unreachable targets for differentiated, defensible IP; HALF-LIFE EXTENSION + NOVEL DELIVERY ARE CRITICAL/DISTINCTIVE: fast clearance needs half-life extension (anti-albumin/Fc), BUT small size enables novel routes (inhaled, intracellular, BBB) — both are valuable IP; HUMANIZATION IS A KEY THERAPEUTIC STEP: humanizing camelid VHHs (reducing immunogenicity) is essential — humanization-method IP is valuable; DISCOVERY PLATFORM IS A DURABLE ENGINE: camelid immunization + library/display selection finds good nanobodies; MIND §112 + ANTIBODY/BISPECIFIC FTO: support nanobody genus claims with data; manage overlap with antibody/bispecific IP; AFFINITY/PENETRATION/DELIVERY/CLINICAL/FTO MATTER AS MUCH AS PATENTS: affinity/specificity, small-size advantages, clinical efficacy, and freedom-to-operate drive value; WHEN TO PATENT: NOVEL NANOBODY/FORMAT/DELIVERY/TARGET WITH MEASURED DATA: file once a candidate shows measured results (affinity/specificity + tissue penetration/cryptic-epitope binding + multivalent format function + half-life/delivery + efficacy) — measured affinity/specificity, tissue penetration/cryptic-epitope reach, and half-life/delivery are the critical nanobody IP metrics; KEY FTO CHECKLIST: Ablynx/Sanofi (foundational VHH — largely expiring; Cablivi); camelid-VHH/shark-VNAR/synthetic-library players; VHH scaffold/format/engineering; humanization; multivalent/multispecific format (overlaps bispecific-antibody IP); specific nanobody/target composition; discovery platform (camelid immunization/library/display); half-life extension (anti-albumin/PEG/Fc) + novel delivery (inhaled/intracellular/BBB); tissue penetration/cryptic epitopes; applications (therapeutic/imaging/diagnostic); §112 enablement; FDA/clinical path.